Wave Life Sciences Outlines Pipeline Progress at 2026 Research Day
Wave Life Sciences provided updates on its RNA-targeted therapeutic pipeline, including plans for its WVE-008 program and clinical data for WVE-007.
Stocks · News reference
Canaccord Genuity Maintains Buy Rating and Raises Price Target for Wave Life Sciences
Canaccord Genuity has reaffirmed its "Buy" rating on Wave Life Sciences and increased its price target for the company's stock from $42 to $44.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Adjusts Price Target on Wave Life Sciences to $29
Oppenheimer maintained an Outperform rating on Wave Life Sciences while adjusting its price target from $32 to $29.
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Business Update
Wave Life Sciences announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including progress on WVE-006 and WVE-007.
8-K filing — Wave Life Sciences, Inc. (WVE)
Filed: 2026-10-27 AccNo: 0001193125-26-432690 Size: 273 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Wave Life Sciences Reports Positive Phase 1 Data for WVE-007 and FDA Alignment for WVE-006
Wave Life Sciences announced positive interim Phase 1 data for its obesity program, WVE-007, and confirmed alignment with the FDA on a registrational pathway for its AATD therapy, WVE-006.
William Blair Initiates Coverage On Wave Life Sciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Wave Life Sciences (NASDAQ:WVE) with a Outperform rating.